<?xml version="1.0" encoding="UTF-8" standalone="yes"?>

<!-- Copyright (c) 2004-2026 Broad Institute, Inc., Massachusetts Institute of Technology, and Regents of the University of California.  All rights reserved.
     See license terms at www.gsea-msigdb.org/gsea/license_terms_list. Please note that certain gene sets have special access terms.
-->
<MSIGDB BUILD_DATE="Jan 29, 2026" VERSION="2026.1.Hs" NAME="export">
    <GENESET STANDARD_NAME="STANELLE_E2F1_TARGETS" SYSTEMATIC_NAME="M16061" HISTORICAL_NAMES="" PMID="11937641" AUTHORS="Stanelle J,Stiewe T,Theseling CC,Peter M,Pützer BM" GEOID="" EXACT_SOURCE="Table 1" GENESET_LISTING_URL="" EXTERNAL_DETAILS_URL="" CHIP="HUMAN_SEQ_ACCESSION" CONTRIBUTOR="Yujin Hoshida" CONTRIBUTOR_ORG="Broad Institute" DESCRIPTION_BRIEF="Genes up-regulated by induction of E2F1 expression in Saos2 (osteosarcoma) cells." DESCRIPTION_FULL="The p16/RB/E2F regulatory pathway, which controls transit through the G1 restriction point of the cell cycle, is one of the most frequent targets of genetic alterations in human cancer. Any of these alterations results in the deregulated expression of the transcription factor E2F, one of the key mediators of cell cycle progression. Under these conditions, E2F1 also participates in the induction of apoptosis by a p53-dependent pathway, and independently of p53. Recently, we identified the p53-homolog p73 as a first direct target of p53-independent apoptosis. Here, we used a cDNA microarray to screen an inducible E2F1-expressing Saos-2 cell line for E2F1 target genes. Expression analysis by cDNA microarray and RT-PCR revealed novel E2F1 target genes involved in E2F1-regulated cellular functions such as cell cycle control, DNA replication and apoptosis. In addition, the identification of novel E2F1 target genes participating in the processes of angiogenesis, invasion and metastasis supports the view that E2F1 plays a central role in many aspects of cancer development. These results provide new insight into the role of E2F1 in tumorigenesis as a basis for the development of novel anti-cancer therapeutics." TAGS="" MEMBERS="AA582021,AA749295,AB007924,AF091433,AI123916,AI378807,AI741331,AI908454,AI917911,AK026075,AL096766,AW007022,BE733577,J02654,L07541,M38690,M73554,NM_002006,NM_003600,NM_003879,NM_005427,NM_005923,NM_005941,U12134,U48801,V00549,X51956,X78817,Y10256" MEMBERS_SYMBOLIZED="ARHGAP4,AURKA,BAD,BAK1,BID,CCND1,CCNE1,CCNE2,CCNO,CD9,CFLAR,ENO2,FGF2,FGFR3,GRAMD4,HSP90B1,IFNA2,MAP3K14,MAP3K5,MMP16,PAWR,PLPPR4,RAD52,RFC3,SERPINF2,TNFSF9,TP53BP2,TP73,VEGFB" MEMBERS_EZID="10309,2026,2247,2261,23151,3440,393,4217,4325,5074,5345,572,578,5893,595,5983,637,6790,7159,7161,7184,7423,8744,8837,898,9020,9134,928,9890" MEMBERS_MAPPING="AA582021,BID,637|AA749295,PAWR,5074|AB007924,PLPPR4,9890|AF091433,CCNE2,9134|AI123916,TP53BP2,7159|AI378807,FGFR3,2261|AI741331,BAK1,578|AI908454,TNFSF9,8744|AI917911,HSP90B1,7184|AK026075,CCNO,10309|AL096766,GRAMD4,23151|AW007022,BAD,572|BE733577,CCNE1,898|J02654,SERPINF2,5345|L07541,RFC3,5983|M38690,CD9,928|M73554,CCND1,595|NM_002006,FGF2,2247|NM_003600,AURKA,6790|NM_003879,CFLAR,8837|NM_005427,TP73,7161|NM_005923,MAP3K5,4217|NM_005941,MMP16,4325|U12134,RAD52,5893|U48801,VEGFB,7423|V00549,IFNA2,3440|X51956,ENO2,2026|X78817,ARHGAP4,393|Y10256,MAP3K14,9020" FILTERED_BY_SIMILARITY="" FOUNDER_NAMES="" REFINEMENT_DATASETS="" VALIDATION_DATASETS="" CATEGORY_CODE="C2" ORGANISM="Homo sapiens" SUB_CATEGORY_CODE="CGP"/>
</MSIGDB>
